A transgenic approach to study argininosuccinate synthetase gene expression

Journal of Biomedical Science

Tsung-Sheng Su¹  Miao-Zeng Huang¹  Shih-Chang Shiue² 

[1] Department of Medical Research, Taipei Veterans General Hospital, 112 Taipei, Taiwan;Institute of Microbiology & Immunology, National Yang-Ming University, 112 Taipei, Taiwan

关键词: Post-transcriptional regulation;    Tissue-specific regulation;    Developmental regulation;    Green fluorescence protein;    Bacterial artificial chromosome;    Transgenic mouse;    Argininosuccinate synthetase;   

Others  :  817591
DOI  :  10.1186/1423-0127-21-42

 received in 2014-03-11, accepted in 2014-04-21,  发布年份 2014

【 摘 要 】

Background

Argininosuccinate synthetase (ASS) participates in urea, nitric oxide and arginine production. Besides transcriptional regulation, a post-transcriptional regulation affecting nuclear precursor RNA stability has been reported. To study whether such post-transcriptional regulation underlines particular temporal and spatial ASS expression, and to investigate how human ASS gene behaves in a mouse background, a transgenic mouse system using a modified bacterial artificial chromosome carrying the human ASS gene tagged with EGFP was employed.

Results

Two lines of ASS-EGFP transgenic mice were generated: one with EGFP under transcriptional control similar to that of the endogenous ASS gene, another with EGFP under both transcriptional and post-transcriptional regulation as that of the endogenous ASS mRNA. EGFP expression in the liver, the organ for urea production, and in the intestine and kidney that are responsible for arginine biosynthesis, was examined. Organs taken from embryos E14.5 stage to young adult were examined under a fluorescence microscope either directly or after cryosectioning. The levels of EGFP and endogenous mouse Ass mRNAs were also quantified by S1 nuclease mapping. EGFP fluorescence and EGFP mRNA levels in both the liver and kidney were found to increase progressively from embryonic stage toward birth. In contrast, EGFP expression in the intestine was higher in neonates and started to decline at about 3 weeks after birth. Comparison between the EGFP profiles of the two transgenic lines indicated the developmental and tissue-specific regulation was mainly controlled at the transcriptional level. The ASS transgene was of human origin. EGFP expression in the liver followed essentially the mouse Ass pattern as evidenced by zonation distribution of fluorescence and the level of EGFP mRNA at birth. However, in the small intestine, Ass mRNA level declined sharply at 3 week of age, and yet substantial EGFP mRNA was still detectable at this stage. Thus, the time course of EGFP expression in the transgenic mice resembled that of the human ASS gene.

Conclusions

We demonstrate that the transgenic mouse system reported here has the merit of sensitivity and direct visualization advantage, and is ideal for annotating temporal and spatial expression profiles and the regulation mode of the ASS gene.

【 授权许可】

   
2014 Shiue et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A: Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003, 270:1887-1899.
• [2]Haines RJ, Pendleton LC, Eichler DC: Argininosuccinate synthase: at the center of arginine metabolism. Int J Biochem Mol Biol 2011, 2:8-23.
• [3]Morris SM Jr: Arginine: beyond protein. Am J Clin Nutr 2006, 83:508S-512S.
• [4]Guei TR, Liu MC, Yang CP, Su TS: Liver-specific cAMP responsive element in the human argininosuccinate synthetase gene. Biochem Biophys Res Commun 2008, 377:257-261.
• [5]Brasse-Lagnel C, Lavoinne A, Loeber D, Fairand A, Bôle-Feysot C, Deniel N, Husson A: Glutamine and interleukin-1β interact at the level of Sp1 and nuclear factor-κB to regulate argininosuccinate synthetase gene expression. FEBS J 2007, 274:5250-5262.
• [6]Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT: Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4. Mol Cancer Ther 2009, 8:3223-3233.
• [7]Tsai TF, Su TS: A nuclear post-transcriptional event responsible for overproduction of argininosuccinate synthetase in a canavanine-resistant variant of a human epithelial cell line. Eur J Biochem 1995, 229:233-238.
• [8]Su TS, Beaudet AL, O’Brien WE: Increased translatable messenger ribonucleic acid for argininosuccinate synthetase in canavanine-resistant human cells. Biochemistry 1981, 20:2956-2960.
• [9]Jacoby LB: Canavanine-resistant variants of human lymphoblasts. Somat Cell Genet 1978, 4:221-231.
• [10]Larsson LI: Immunocytochemistry: Theory and Practice. Boca Raton, Florida: CRC Press Inc; 1988.
• [11]Sambrook J, Russell DW: Molecular Cloning: A Laboratory Manual. 3rd edition. Cold Spring Harbor Laboratory Press: Cold Spring Harbor; 2001.
• [12]Bourgeois P, Harlin JC, Renouf S, Goutal I, Fairand A, Husson A: Regulation of argininosuccinate synthetase mRNA level in rat foetal hepatocytes. Eur J Biochem 1997, 249:669-674.
• [13]Hutmacher DW, Dokland T, Ng MML: Techniques in Microscopy for Biomedical Applications. 1st edition. Singapore: World Scientific Pub Co Inc; 2006.
• [14]Dingemanse MA, De Jonge WJ, De Boer PAJ, Mori M, Lamers WH, Moorman AF: Development of the ornithine cycle in rat liver: Zonation of a metabolic pathway. Hepatology 1996, 24:407-411.
• [15]Saheki T, Yagi Y, Sase M, Nakano K, Sato E: Immunohistochemical localization of argininosuccinate synthetase in the liver of control and citrullinemic patients. Biomed Res Tokyo 1983, 4:235-238.
• [16]Morris SM Jr, Sweeney WE Jr, Kepka DM, O’Brien WE, Avner ED: Localization of arginine biosynthetic enzymes in renal proximal tubules and abundance of mRNA during development. Pediatr Res 1991, 29:151-154.
• [17]Kriz W, Koepsell H: The structural organization of the mouse kidney. Anat Embryol 1974, 144:137-163.
• [18]Georgas K, Rumballe B, Wilkinson L, Chiu HS, Lesieur E, Gilbert T, Little MH: Use of dual section mRNA in situ hybridisation/immunohistochemistry to clarify gene expression patterns during the early stages of nephron development in the embryo and in the mature nephron of the adult mouse kidney. Histochem Cell Biol 2008, 130:927-942.
• [19]Morris SM Jr: Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002, 22:87-105.
• [20]De Jonge WJ, Dingemanse MA, De Boer PAJ, Lamers WH, Moorman AFM: Arginine-metabolizing enzymes in the developing rat small intestine. Pediatr Res 1998, 43:442-451.
• [21]Tsai TF: Regulation of Human Argininosuccinate Synthetase Gene Expression. PhD Thesis. Taiwan: National Yang-Ming University, Institute of Microbiology & Immunology; 1995.
• [22]Ali Baig MM, Habibullah CM, Swamy M, Hassan SI, Zaman TU, Ayesha Q, Devi BG: Studies on urea cycle enzyme levels in the human fetal liver at different gestational ages. Pediatr Res 1992, 31:143-145.
• [23]Stoll B, Henry J, Reeds PJ, Yu H, Jahoor F, Burrin DG: Catabolism dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed piglets. J Nutr 1998, 128:606-614.
• [24]Köhler ES, Sankaranarayanan S, van Ginneken CJ, van Dijk P, Vermeulen JL, Ruijter JM, Lamers WH, Bruder E: The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of arginine-synthesizing and -catabolizing enzymes. BMC Dev Biol 2008, 8:107-122. BioMed Central Full Text
• [25]Wilson MD, Barbosa-Morais NL, Schmidt D, Conboy CM, Vanes L, Tybulewicz VLJ, Fisher EMC, Tavaré S, Odom DT: Species-specific transcription in mice carrying human chromosome 21. Science 2008, 322:434-438.
• [26]Phillips MM, Sheaff MT, Szlosarek PW: Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 2013, 45:251-262.